Detalles de la búsqueda
1.
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Blood
; 142(17): 1438-1447, 2023 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37418685
2.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Ann Hematol
; 103(1): 125-132, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37731147
3.
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.
Ann Hematol
; 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38805036
4.
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
Br J Haematol
; 185(5): 944-947, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478966
5.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med
; 13(7): e7071, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558233
6.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38849344
7.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396807
8.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666982
9.
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.
Cancers (Basel)
; 14(1)2021 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008361
10.
Mediastinal Rosai-Dorfman Disease With Widespread Lesions: When Surgical Biopsy Is Needed.
Ann Thorac Surg
; 109(1): e45-e47, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31207246
11.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
; 7(6): e456-e468, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359506
12.
[Peer review about gastro-esophageal reflux disease in primary care: epidemiology, diagnostic and therapeutic management]. / Revisione tra pari della malattia da reflusso gastro-esofageo in medicina generale: parametri epidemiologici e gestione diagnostico-terapeutica.
Recenti Prog Med
; 97(2): 74-8, 2006 Feb.
Artículo
en Italiano
| MEDLINE | ID: mdl-16671271
13.
Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.
Mediterr J Hematol Infect Dis
; 7(1): e2015001, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25574360
Resultados
1 -
13
de 13
1
Próxima >
>>